![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SCN1A |
Gene summary for SCN1A |
![]() |
Gene information | Species | Human | Gene symbol | SCN1A | Gene ID | 6323 |
Gene name | sodium voltage-gated channel alpha subunit 1 | |
Gene Alias | DEE6 | |
Cytomap | 2q24.3 | |
Gene Type | protein-coding | GO ID | GO:0001508 | UniProtAcc | P35498 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6323 | SCN1A | RNA-P10T2-P10T2-1 | Human | Lung | AAH | 7.47e-04 | 1.04e+00 | -0.1271 |
6323 | SCN1A | RNA-P10T2-P10T2-2 | Human | Lung | AAH | 4.14e-04 | 9.65e-01 | -0.1406 |
6323 | SCN1A | RNA-P10T2-P10T2-3 | Human | Lung | AAH | 1.34e-03 | 9.21e-01 | -0.1408 |
6323 | SCN1A | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 8.78e-16 | 9.56e-01 | -0.2116 |
6323 | SCN1A | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 5.16e-14 | 1.12e+00 | -0.1941 |
6323 | SCN1A | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 3.17e-11 | 1.02e+00 | -0.2107 |
6323 | SCN1A | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 1.03e-20 | 1.07e+00 | -0.2119 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Lung | ![]() | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ | ||
IAC: Invasive lung adenocarcinoma | ||
MIA: Minimally invasive adenocarcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003004812 | Lung | AIS | actin filament-based movement | 25/1849 | 127/18723 | 5.99e-04 | 9.14e-03 | 25 |
GO:008600111 | Lung | AIS | cardiac muscle cell action potential | 16/1849 | 76/18723 | 2.70e-03 | 2.72e-02 | 16 |
GO:000301211 | Lung | AIS | muscle system process | 63/1849 | 452/18723 | 3.18e-03 | 3.05e-02 | 63 |
GO:003004822 | Lung | AAH | actin filament-based movement | 12/613 | 127/18723 | 9.53e-04 | 2.94e-02 | 12 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SCN1A | SNV | Missense_Mutation | novel | c.4276C>T | p.Leu1426Phe | p.L1426F | P35498 | protein_coding | tolerated(0.06) | probably_damaging(1) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
SCN1A | SNV | Missense_Mutation | c.3968C>A | p.Pro1323His | p.P1323H | P35498 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
SCN1A | SNV | Missense_Mutation | novel | c.1808G>T | p.Ser603Ile | p.S603I | P35498 | protein_coding | tolerated(0.07) | possibly_damaging(0.549) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
SCN1A | SNV | Missense_Mutation | c.2396T>C | p.Val799Ala | p.V799A | P35498 | protein_coding | deleterious(0.05) | benign(0.097) | TCGA-B5-A0JR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SCN1A | SNV | Missense_Mutation | c.1224N>A | p.Phe408Leu | p.F408L | P35498 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
SCN1A | SNV | Missense_Mutation | rs121917921 | c.5348C>T | p.Ala1783Val | p.A1783V | P35498 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-B5-A0K6-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SCN1A | SNV | Missense_Mutation | novel | c.1252N>G | p.Ile418Val | p.I418V | P35498 | protein_coding | deleterious(0.01) | probably_damaging(0.981) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SCN1A | SNV | Missense_Mutation | c.1927A>G | p.Ser643Gly | p.S643G | P35498 | protein_coding | tolerated(0.07) | benign(0.079) | TCGA-B5-A11H-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Hormone Therapy | megace | SD | |
SCN1A | SNV | Missense_Mutation | c.4451N>G | p.Asp1484Gly | p.D1484G | P35498 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B5-A11N-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SCN1A | SNV | Missense_Mutation | c.1481N>T | p.Ala494Val | p.A494V | P35498 | protein_coding | tolerated(0.09) | probably_damaging(0.998) | TCGA-B5-A11O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6323 | SCN1A | DRUGGABLE GENOME, ION CHANNEL | levetiracetam | LEVETIRACETAM | 23859570,21747585,28753467,25155934 | |
6323 | SCN1A | DRUGGABLE GENOME, ION CHANNEL | ZONISAMIDE | ZONISAMIDE | ||
6323 | SCN1A | DRUGGABLE GENOME, ION CHANNEL | blocker | CHEMBL1201754 | RUFINAMIDE | |
6323 | SCN1A | DRUGGABLE GENOME, ION CHANNEL | blocker | 135652715 | SAXITOXIN | |
6323 | SCN1A | DRUGGABLE GENOME, ION CHANNEL | blocker | CHEMBL1200586 | PRILOCAINE HYDROCHLORIDE | |
6323 | SCN1A | DRUGGABLE GENOME, ION CHANNEL | blocker | CHEMBL861 | MEPHENYTOIN | |
6323 | SCN1A | DRUGGABLE GENOME, ION CHANNEL | inhibitor | 135651976 | ||
6323 | SCN1A | DRUGGABLE GENOME, ION CHANNEL | blocker | 135652722 | TETRODOTOXIN | |
6323 | SCN1A | DRUGGABLE GENOME, ION CHANNEL | phenytoin | PHENYTOIN | 17001291 | |
6323 | SCN1A | DRUGGABLE GENOME, ION CHANNEL | blocker | CHEMBL3545209 | NKTR-171 |
Page: 1 2 3 4 5 6 7 8 9 |